Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2018 | short review | Ausgabe 2/2018 Open Access

memo - Magazine of European Medical Oncology 2/2018

Chronic lymphocytic leukemia at ASH 2017

memo - Magazine of European Medical Oncology > Ausgabe 2/2018
MD David Wanner, Michael Steurer


At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia.
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018Zur Ausgabe